Discovery & Preclinical
Set a clear product strategy, define a credible clinical and regulatory path, select the right asset and get ready for first-in-human trials with confidence
Respiratory drug development and commercialisation encompass improvements in existing classes of systemic and inhaled treatments as well as novel agents for common and rare respiratory conditions. Finding effective and safe new classes of drugs to treat asthma and COPD remains difficult.
tranScrip teams have expertise in all major respiratory indications from asthma, COPD and allergy to orphan indications such as cystic fibrosis or idiopathic pulmonary fibrosis.
We are helping our clients address clinical and regulatory challenges, differentiate their products and realise drug development and lifecycle goals.
We provide strategic expertise, therapeutic experience and operational excellence across the entire product lifecycle.
Set a clear product strategy, define a credible clinical and regulatory path, select the right asset and get ready for first-in-human trials with confidence
Implement first-in-human trials, interpreting emerging data and adapting plans as needed. Ensure robust decisions, including clear proof-of-concept
Design medically-endorsed pivotal programs that stand up to global regulatory and commercial scrutiny. Navigate issues in implementation
Interpret data, assess benefit/risk and secure regulatory approvals, successfully bring your medicine to market. Ensure strong lifecycle management
Get in touch to see how our senior cross-functional experts can help you reduce risk, protect value, and move forward with confidence.
